-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Pancreatic Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Pancreatic Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Pancreatic Cancer Drug Details: P-MUC1CALLO-1 is under development for...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Non-Small Cell Lung Cancer Drug Details: P-MUC1CALLO-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. P-MUC1C-ALLO1 in Triple-Negative Breast Cancer (TNBC) Drug Details: P-MUC1CALLO-1...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Avelumab in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Avelumab in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Avelumab in Refractory Acute Myeloid Leukemia Drug Details: Avelumab...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Ivosidenib in Low-Grade Glioma
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Ivosidenib in Low-Grade Glioma report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Ivosidenib in Low-Grade Glioma Drug Details: Ivosidenib (Tibsovo / AG-120) acts...
-
Product Insights
Salivary Gland Cancer – Drugs In Development, 2023
Global Markets Direct’s, ‘Salivary Gland Cancer - Drugs In Development, 2023’, provides an overview of the Salivary Gland Cancer pipeline landscape. The report provides comprehensive information on the therapeutics under development for Salivary Gland Cancer, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the...
-
Product Insights
Hemophilia A (Factor VIII Deficiency) – Drugs In Development, 2023
Global Markets Direct’s, ‘Hemophilia A (Factor VIII Deficiency) - Drugs In Development, 2023’, provides an overview of the Hemophilia A (Factor VIII Deficiency) pipeline landscape. The report provides comprehensive information on the therapeutics under development for Hemophilia A (Factor VIII Deficiency), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest...